Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

138.76USD
22 May 2019
Change (% chg)

$0.64 (+0.46%)
Prev Close
$138.12
Open
$138.35
Day's High
$138.95
Day's Low
$137.49
Volume
2,156,404
Avg. Vol
2,007,794
52-wk High
$148.97
52-wk Low
$118.62

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson Says South Carolina Jury Clears It Of Liability In Lawsuit Alleging Asbestos In Talc Caused Woman's Cancer
Tuesday, 21 May 2019 

Johnson & Johnson ::JOHNSON & JOHNSON SAYS SOUTH CAROLINA JURY CLEARS IT OF LIABILITY IN LAWSUIT ALLEGING ASBESTOS IN TALC CAUSED WOMAN'S CANCER.  Full Article

Minerva Neurosciences Announces Positive Top Line Results In Phase 2B Clinical Trial With Seltorexant (Min-202)
Monday, 13 May 2019 

May 13 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES ANNOUNCES POSITIVE TOP LINE RESULTS IN PHASE 2B CLINICAL TRIAL WITH SELTOREXANT (MIN-202) IN TREATMENT OF DEPRESSED PATIENTS WITH AN INADEQUATE RESPONSE TO SSRIS AND SNRIS.MINERVA NEUROSCIENCES INC - SELTOREXANT WAS WELL TOLERATED, WITH ADVERSE EVENTS SIMILAR TO OR LOWER THAN RATE OBSERVED IN PLACEBO GROUP.MINERVA NEUROSCIENCES INC - SELTOREXANT DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT IN MADRS SCORES AT 6 WEEKS COMPARED TO PLACEBO.MINERVA NEUROSCIENCES INC - SELTOREXANT IMPROVES DEPRESSIVE SYMPTOMS AND SLEEP FUNCTION.MINERVA NEUROSCIENCES INC - SELTOREXANT DEMONSTRATES IMPROVEMENT IN SYMPTOMS OF MDD PATIENTS NOT ADEQUATELY TREATED BY SSRIS AND/OR SNRIS.MINERVA NEUROSCIENCES - TOP LINE RESULTS FROM SEPARATE PHASE 2B TRIAL OF SELTOREXANT IN INSOMNIA ARE EXPECTED TO BE ANNOUNCED LATER THIS QUARTER.  Full Article

J&J Says At Annual Meeting, Shareholders Did Not Approve Proposal For Clawback Disclosure
Friday, 26 Apr 2019 

April 26 (Reuters) - Johnson & Johnson ::J&J - AT THE ANNUAL MEETING OF THE SHAREHOLDERS, SHAREHOLDERS DID NOT APPROVE THE SHAREHOLDER PROPOSAL FOR CLAWBACK DISCLOSURE.J&J - AT THE ANNUAL MEETING, SHAREHOLDERS DID NOT APPROVE THE SHAREHOLDER PROPOSAL FOR EXECUTIVE COMPENSATION AND DRUG PRICING RISKS.J&J - AT THE ANNUAL MEETING OF THE SHAREHOLDERS, SHAREHOLDERS ELECTED ALL 12 DIRECTOR NOMINEES NAMED IN 2019 PROXY STATEMENT TO BOARD.  Full Article

Johnson & Johnson Announces Dividend Increase Of 5.6%
Thursday, 25 Apr 2019 

April 25 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON ANNOUNCES DIVIDEND INCREASE OF 5.6%.SETS QUARTERLY DIVIDEND OF $0.95 PER SHARE.  Full Article

Arrowhead Pharmaceuticals Earns $25 Million Milestone Payment From Janssen
Wednesday, 24 Apr 2019 

April 24 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD BEGINS TRIPLE COMBINATION COHORT IN CHRONIC HBV PATIENTS AND EARNS $25 MILLION MILESTONE PAYMENT FROM JANSSEN.ARROWHEAD - BEGUN DOSING IN NEW TRIPLE COMBINATION COHORT THAT INCLUDES JNJ-3989 AND ADDITIONAL UNDISCLOSED AGENTS SELECTED BY JANSSEN PHARMACEUTICALS.ARROWHEAD - ELIGIBLE TO RECEIVE REMAINING $25 MILLION UPON INITIATION OF A PHASE 2 STUDY BY JANSSEN.  Full Article

Bausch Health And Johnson & Johnson Reach Deal Regarding Scope Of Indemnification Relating To Shower To Shower Covered Matters
Tuesday, 23 Apr 2019 

April 23 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH - CO AND JOHNSON & JOHNSON REACHED DEAL ON APRIL 17, REGARDING SCOPE OF INDEMNIFICATION RELATING TO SHOWER TO SHOWER COVERED MATTERS.BAUSCH HEALTH COMPANIES - AGREED TO DISMISS DEMAND FOR ARBITRATION THAT CO FILED AGAINST JOHNSON & JOHNSON TO ASSERT ITS RIGHTS TO INDEMNIFICATION.BAUSCH HEALTH COMPANIES INC - JOHNSON & JOHNSON WILL FULLY INDEMNIFY COMPANY IN COVERED MATTERS.BAUSCH HEALTH COMPANIES - DON'T BELIEVE THAT COVERED MATTERS WILL HAVE A MATERIAL IMPACT ON COMPANY'S FINANCIAL RESULTS GOING FORWARD.BAUSCH HEALTH COMPANIES - COVERED MATTERS INCLUDE PERSONAL INJURY & PRODUCTS LIABILITY ACTIONS ARISING FROM ALLEGED EXPOSURE TO SHOWER TO SHOWER BEFORE MARCH 2020.BAUSCH HEALTH - COVERED MATTERS INCLUDE CONSUMER FRAUD, CONSUMER PROTECTION, FALSE ADVERTISING, REGULATORY ACTIONS DUE TO MANUFACTURE, USE/SALE OF SHOWER TO SHOWER UP TO SEPT. 9, 2012.  Full Article

J&J Says 800 Sites Now Certified For New Depression Drug Spravato
Tuesday, 16 Apr 2019 

April 16 (Reuters) - Johnson & Johnson ::J&J EXECUTIVE SAYS GLOBAL PHARMA GROWTH CONTINUED TO BE DRIVEN BY VOLUME AND NOT PRICE: CONF. CALL.J&J SEES IMPACT OF GENERIC/ BIOSIMILAR COMPETITION AT THE LOWER END OF ITS PREVIOUS RANGE OF $3 BILLION-$3.5 BILLION.J&J SAYS 800 SITES NOW CERTIFIED FOR NEW DEPRESSION DRUG SPRAVATO.J&J EXPECTS TO SEE LARGEST IMPACT FROM GENERIC AND BIOSIMILAR EROSION IN 2019.  Full Article

Janssen Says Invokana Significantly Reduces Risk Of Renal Failure In Patients With Type 2 Diabetes And Chronic Kidney Disease In Phase 3 Study
Monday, 15 Apr 2019 

April 14 (Reuters) - Johnson & Johnson ::JANSSEN PHARMACEUTICAL - NEW RESULTS FROM PHASE 3 CREDENCE STUDY SHOWS INVOKANA DEMONSTRATED 30 PERCENT REDUCTION IN RISK OF PRIMARY COMPOSITE ENDPOINT.JANSSEN - STUDY RESULTS ALSO SHOWED INVOKANA REDUCED RISK OF SECONDARY CV ENDPOINT.JANSSEN - INVOKANA SIGNIFICANTLY REDUCES RISK OF RENAL FAILURE IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE IN PHASE 3 STUDY.  Full Article

Qiagen Launches Companion Diagnostic Using FGFR Alterations To Help Guide Treatment Of Metastatic Urothelial Cancer
Friday, 12 Apr 2019 

April 12 (Reuters) - Qiagen NV ::QIAGEN LAUNCHES FIRST FDA-APPROVED COMPANION DIAGNOSTIC USING FGFR ALTERATIONS TO HELP GUIDE THE TREATMENT OF METASTATIC UROTHELIAL CANCER.QIAGEN NV - NOVEL THERASCREEN FGFR RGQ RT-PCR KIT WILL AID IN IDENTIFYING PATIENTS ELIGIBLE FOR TREATMENT WITH BALVERSA, DEVELOPED BY JANSSEN.  Full Article

FDA Says Granted Accelerated Approval To Janssen's Balversa
Friday, 12 Apr 2019 

April 12 (Reuters) - FDA::FDA APPROVES FIRST TARGETED THERAPY FOR METASTATIC BLADDER CANCER.FDA - GRANTED ACCELERATED APPROVAL TO BALVERSA (ERDAFITINIB).FDA - BALVERSA WAS ALSO GRANTED BREAKTHROUGH THERAPY DESIGNATION.FDA - ALSO APPROVED THERASCREEN FGFR RGQ RT-PCR KIT, DEVELOPED BY QIAGEN MANCHESTER FOR USE AS COMPANION DIAGNOSTIC WITH BALVERSA FOR INDICATION.  Full Article

Companies lobby U.S. Congress on carbon tax; senator expects bill in weeks

WASHINGTON, May 22 Representatives from more than 70 companies met with U.S. lawmakers on Wednesday to push for a tax on carbon emissions to fight climate change, and a senator said bipartisan legislation containing such a plan could be introduced in weeks.